Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
July 19, 2017
Paratek Pharmaceuticals to Report Second Quarter 2017 Financial Results and Provide Update on Clinical Progress on August 2, 2017
BOSTON, July 19, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon ...
July 19, 2017
BARDA Upsizes Contract with MediWound and Exercises Option to Fund Further NexoBrid® Indications
YAVNE, Israel, July 19, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in ...
July 19, 2017
CymaBay Announces Pricing of Public Offering of Common Stock
NEWARK, Calif., July 19, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
July 19, 2017
Data From BioTime’s Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting
ALAMEDA, Calif. -- (BUSINESS WIRE) -- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract ...
July 19, 2017
CTD Holdings Announces First Patient Dosed in Phase I/II Clinical Trial to Evaluate Trappsol(R) Cyclo(TM) in Niemann-Pick Disease Type C
ALACHUA, FL--(Marketwired - July 19, 2017) - CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of disease, today ...
July 19, 2017
Investigational New Drug Application for RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder Submitted to FDA by Allergan
RA’ANANA, Israel, and NEW YORK, July 19, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs ...
July 19, 2017
Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company
NEW YORK -- (BUSINESS WIRE) -- Immune Pharmaceuticals (IMNP) (“Immune”) today confirmed it is continuing to structure and pursue a spin-off of Cytovia, Inc. (“Cytovia”), its ...
July 18, 2017
Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections
BOSTON, July 17, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK) announced today positive top-line results from a pivotal Phase 3 clinical study comparing its ...
July 18, 2017
CymaBay Announces Proposed Public Offering of Common Stock
NEWARK, Calif., July 17, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
July 18, 2017
BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS
HACKENSACK, N.J. and PETACH TIKVA, Israel, July 18, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...
July 18, 2017
BioTime to Host Key Opinion Leader Event on the Topic of Dry AMD in New York City
ALAMEDA, Calif.--(BUSINESS WIRE) -- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced today that it will host ...
July 18, 2017
DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
VANCOUVER, British Columbia and MENLO PARK, Calif., July 18, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the ...
July 18, 2017
Kitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda® in Immune-Oncology Preclinical Model
TEL AVIV, Israel, July 18, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (KTOV), an innovative biopharmaceutical company, today announced  results of a pre-clinical study ...
July 18, 2017
Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs
JERUSALEM, July 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Simon ...
July 14, 2017
CTD Holdings to Present at 25th Annual Family Conference of the National Niemann-Pick Disease Foundation
ALACHUA, FL--(Marketwired - July 13, 2017) - CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, ...
July 14, 2017
BioLife Solutions CryoStor® Cell Freeze Media Embedded in Invossa™: First Approved Cell and Gene Therapy for Osteoarthritis
BOTHELL, Wash., July 13, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), the leading supplier of pre-formulated, clinical grade cell and tissue hypothermic storage and cryopreservation freeze ...
July 13, 2017
Aurinia Resolves Temporary Non-Compliance with Nasdaq’s Audit Committee Composition Rule
VICTORIA, British Columbia--(BUSINESS WIRE) -- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced the receipt of a letter from The NASDAQ Stock ...
July 13, 2017
BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery
ALAMEDA, Calif. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE) -- AgeX Therapeutics (“AgeX”), a subsidiary of BioTime, Inc. (NYSE MKT:BTX) with a focus on developing new therapies in the ...
July 13, 2017
CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma
MONMOUTH JUNCTION, N.J., July 13, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a leader in critical care immunotherapy specializing in blood purification, today announced that it ...
July 13, 2017
IMMUNE Pharmaceuticals’ Oncology Subsidiary, CYTOVIA, Announces the Filing of a World-Wide Patent Protecting the Use of Ceplene® in Acute Myeloid Leukemia (AML) and Other Hematological Cancers with Mutated NPM1
NEW YORK--(BUSINESS WIRE) -- Cytovia, Inc. (“Cytovia”) the oncology subsidiary of Immune Pharmaceuticals Inc. (IMNP) ("Immune" or the “Company”), a clinical stage biopharmaceutical company, announced the ...
Page 105 of 117